ArticleFrontiers in oncology2026
Analysis of the expression of FAP, Caveolin1, and CPXM2 and prognostic significance in gastric cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study sought to examine the expression levels and clinical relevance of fibroblast activation protein alpha (FAP), caveolin-1 (CAV1), and carboxypeptidase X member 2 (CPXM2) in gastric cancer (GC) and adjacent tissues. Methods: Multiplex immunofluorescence (mIF) was performed on tissue microarrays to evaluate the expression of FAP, CAV1, CPXM2, and cytokeratin (CK) in GC specimens. Correlations among these markers and their associations with clinicopathological features and survival outcomes were analyzed. Results: This investigation discovered that CAV1 was predominantly expressed in stromal cells, whereas CPXM2 was expressed in both epithelial and stromal cells. The number and proportion of FAP Conclusions: These findings suggest that CAV1 and CPXM2 are differentially expressed in GC and associated with patient prognosis, highlighting them as potential candidates for further functional investigation in the context of GC progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.